October 13, 2023
Sanofi: amlitelimab significantly improved signs and symptoms of moderate-to-severe atopic dermatitis
Positive results from a Phase 2b study (STREAM-AD) showed that amlitelimab significantly improved signs and symptoms of moderate-to-severe atopic dermatitis in adults whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach.